3 ASX 200 buy-the-dip opportunities recommended by brokers today

Here are three ASX 200 shares that brokers say are buys following share price tumbles or stagnation in 2023.

| More on:
Woman flexes muscles after donating blood.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Who doesn't love a great ASX 200 buy-the-dip opportunity?

As 2023 draws to a close and we all take a look at the performance of our portfolios this year, is it time to consider buying some new stocks for extra diversification?

And which ASX 200 shares are ripe for investment after languishing or being oversold in 2023?

Well, some top brokers are going to help us out with this question.

Here are three ASX 200 shares that brokers say are buys following share price tumbles or stagnation in 2023.

50% upside possible on Qantas shares

The Qantas Airways Limited (ASX: QAN) share price is down 9.3% in the year to date compared to a 9.4% uplift in the ASX 200. It is currently trading at $5.39, up 0.65% on Thursday.

As the chart below shows, Qantas shares remain in a pronounced dip.

The stock's 52-week high is $6.94 and its 52-week low is $4.67.

Qantas has faced a mountain of challenges this year that have damaged its reputation. Customers have vented fury over poor service, cancelled flights, lost baggage and the expiration of COVID-19 credits amid retiring CEO Alan Joyce receiving $21.4 million in earnings over FY23.

There was also a class action lawsuit regarding the handling of cancelled flights during the pandemic. The Federal Court ruled the airline had illegally sacked 1,683 workers, and the Australian Competition and Consumer Commission (ACCC) is suing Qantas for allegedly selling tickets for cancelled flights.

Goldman Sachs has a conviction buy rating on the beleaguered ASX 200 travel share. The broker's 12-month share price target is $8.25, indicating a potential upside of 53% for investors who buy today.

ResMed shares rebounding but there's still time to buy

The ResMed CDI (ASX: RMD) share price is down 17.1% in the year to date. It is currently trading at $25.23, down 0.86% on Thursday.

There has been some recovery in the ResMed share price recently, but it is still well down on its 52-week high of $36.37. The 52-week low is $21.14.

This year's sell-off is largely related to market jitters over the impact of the wonder weight-loss drug, Ozempic.

Originally a diabetes medication, Ozempic is now also being prescribed for obesity, and investors are concerned this may reduce demand for ResMed's sleep apnea devices given obesity is a common precursor to sleep apnea.

Macquarie has an outperform rating on ResMed shares with a $33.40 price target. This implies a potential 32.4% upside for investors who buy now.

Stagnated ASX 200 blue-chip giant a buy right now

The CSL Limited (ASX: CSL) share price has risen by just 1.5% in the year to date. It is currently trading at $286.11, up 0.16% on Thursday.

Its 52-week high is $314.28 and its 52-week low is $228.65.

The healthcare giant has also been affected by Ozempic, given recent studies show it may also be an effective treatment for chronic kidney disease (CKD).

Two years ago, CSL forked out $18 billion to acquire CKD business, Vifor.

Morgan Stanley analyst Sean Laaman also attributes CSL's lacklustre share price performance in 2023 to other product disruption threats and a slower recovery in its plasma collections following COVID-19.

The best time to buy would have been late October when the stock was in the $230 range. However several top brokers say CSL shares are still attractive at today's price level.

Goldman Sachs has a buy rating and a 12-month price target of $309. Citi also has a buy rating and a more bullish $325 price target, implying a potential 13.6% uplift for investors in 2024.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL and Macquarie Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

These ASX 200 shares could rise 20% to 50%

Big returns could be on the cards for owners of these shares according to analysts.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Why this ASX 100 stock can rise 14% to a new 52-week high

Goldman Sachs thinks investors should be buying this top stock now.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Goldman says buy this ASX 200 share for a 14% annual return

This overlooked stock could be a good option for investors according to the broker.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A wine technician in overalls holds a glass of red wine up to the light and studies is closely with large wine barrels in the background, stored in a brick walled wine cellar.
Broker Notes

2 undervalued ASX 200 shares with 'significant catalysts ahead'

We reveal the ASX 200 coal and wine stocks that this fund manager has selected for additional investment.

Read more »

A female coal miner wearing a white hardhat and orange high-vis vest holds a lump of coal and smiles as the Whitehaven Coal share price rises today
Broker Notes

1 ASX 200 energy stock with 'minimal competition' to buy right now

This stock is trading 30% lower than its 2022 record high.

Read more »